Not so delusional therapy – Liberation

Mescaline, lsd, ketamine, ayahuascapsilocybin, MDMA… a number of psychedelic substances have allowed for hundreds of years, even millennia, to open the chakras or to dive the consumer In a journey beyond the borders of the known world. But these molecules, often struck by the seal of illegality, can also have therapeutic virtues: to treat anxiety, depression and other mental disorders. It is around these properties that we have witnessed, in recent years, to a renewed interest in hallucinogenic substances or which alter the state of consciousness on the part of white blouses around the world. Until France: in February 2024, the Nîmes University Hospital undertook a clinical trial around psilocybin, with effects similar to those of the LSD, in patients with disorders of alcohol use associated with depression. This is the first clinical trial for fifty years around psychedelics in France.

In his test published in January, Travel to psychedelic medicines (Grasset), journalist Dominique Nora, great reporter to New obs, tells the rebirth of these therapeutic investigations. HAS Release, She assures that this medicine is getting out of the